Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
asaretoclax
- Development stage
- Discontinued
- Lead developer
- Zentalis Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Asaretoclax (ZN-d5) is an orally bioavailable, selective small molecule inhibitor of B-cell lymphoma 2 (BCL-2), an anti-apoptotic protein frequently overexpressed in various hematologic malignancies. By binding to BCL-2, asaretoclax restores the apoptotic signaling pathway, leading to the programmed cell death of cancer cells. It is being developed by Zentera Therapeutics (a joint venture between Zentalis Pharmaceuticals and a consortium of investors) primarily for the treatment of B-cell malignancies, including non-Hodgkin lymphoma (NHL) and potentially acute myeloid leukemia (AML). Clinical development is currently focused on the Chinese market, where it is being evaluated in Phase I studies for safety, pharmacokinetics, and clinical activity in subjects with relapsed or refractory NHL.
- Other names
- BCL-2 inhibitor ZN-d5BCL2 inhibitor ZN-d5BCL 2 inhibitor ZN-d5ZN-d5ZN-d-5ZN-d 5
02
Targets
BCL-2 (BCL-2 family)
Beyond the preview
Go deeper on asaretoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on asaretoclax.